share_log

Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen

Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen

集中神經退行性疾病的公司通過 Wilbur Ross 支持的 SPAC 上市，加入阿爾茨海默氏症競賽以競爭生物原
Benzinga Real-time News ·  2023/01/18 10:12
  • Neurodegenerative diseases-focused Aprinoia Therapeutics has announced a business combination with Ross Acquisition Corp II (NYSE:ROSS), a special-purpose acquisition company founded by former Commerce Secretary Wilbur Ross, at an equity value of $280 million.
  • Wilbur Ross has personally invested $7.5 million through convertible notes and committed up to $12.5 million of capital infusion at the closing.
  • Aprinoia, founded in 2015, is a clinical-stage biotech company developing novel therapeutics and precision diagnostics for treating neurodegenerative diseases.
  • The company has collaborations with Biogen Inc (NASDAQ:BIIB) and Bristol Myers Squibb & Co's (NYSE:BMY) Celgene, which includes certain non-exclusive license agreements on its lead tau PET tracer, APN-1607.
  • "Aprinoia's tau approach is potentially complementary to beta-Amyloid-based products like Lecanemab. We're encouraged by the progress made in this field over the last two years and believe we're partnering with APRINOIA at the right time to continue advancing this field," added Wilbur Ross, CEO of ROSS.
  • Recently, Biogen's second Alzheimer's disease treatment, Leqembi (lecanemab), scored FDA approval in patients with mild cognitive impairment or mild dementia stage of the disease.
  • Concurrently, Aprinoia has out-licensed the China rights of APN-1607 to a large pharmaceutical company, whereby such company licensee has executed a binding term sheet agreeing to lead the product through its current Phase 3 trial in AD and target 2024 for commercialization of APN-1607 in China.
  • The licensee has committed approximately $8 million and RMB 14 million as an upfront payment, milestone payments, and royalties.
  • Aprinoia will continue to lead the development of APN-1607 in other jurisdictions.
  • APN-1607 is in a Phase 2 trial for Alzheimer's Disease and is preparing for a Phase 3 trial in Progressive Supranuclear Palsy in the U.S.
  • Price Action: ROSS shares are up 0.10% at $10.16 on the last check Wednesday.
  • 集中神經退行性疾病 阿普利諾症治療 已經宣布與業務合併 羅斯收購公司 II 紐約證券交易所代碼：ROSS），由前商務部長創立的特殊用途收購公司 威尔伯·罗斯，股本價值為 2.8 億美元。
  • 威爾伯·羅斯（Wilbur Ross）親自通過可換股票據投資了 750 萬美元，並在收盤時承諾高達 12.5 萬美元的資本注入。
  • Aprinoia 成立於 2015 年，是一家臨床階段的生物技術公司，致力於開發用於治療神經退行性疾病的新型治療和精確診斷。
  • 該公司與合作 生物科技公司 (納斯達克:比 IB) 和 布里斯托尔·迈尔斯奎布 (紐約證券交易所:BMY) 塞爾金, 其中包括其鉛 PET 示踪劑某些非獨家許可協議, APN-1607.
  • 「阿普利諾症的 tau 方法可能與基於 β-澱粉樣蛋白的產品（如卵磷脂）相互補充。我們對過去兩年在這一領域取得的進展感到鼓舞，並相信我們正在合適的時間與 APRINOIA 合作，繼續推進這一領域。」
  • 最近，Biogen 的第二次阿爾茨海默病治療方法 Leqembi（講座單抗）在輕度認知障礙或輕度癡呆階段患者中獲得了 FDA 的批准。
  • 同時，Aprinoia 已將 APN-1607 的中國權利授權出予一家大型製藥公司，而該公司被授權人已簽署具有約束力的條款單，同意引導該產品通過公元目前的 3 期試驗，目標是 2024 年在中國進行 APN-1607 商業化。
  • 被授權人已承諾約 800 萬美元和 1,400 萬元人民幣作為前期付款，里程碑付款和特許權使用費。
  • 亞普利諾症將繼續在其他司法管轄區領導 APN-1607 的發展。
  • APN-1607 正在進行阿爾茨海默氏病的第二期試驗，正在準備在美國進行漸進性超清除性癱瘓的 3 期試驗。
  • 價格行動： 上次檢查週三，羅斯股價上漲了 0.10%，價格為 10.16 美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論